AbbVie (ABBV)
NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
$254.64-0.05%
Close 2026-07-07 · 1-day change
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→NYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-07-07
Reading ABBV? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track ABBV free→Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRevenue is growing steadily — about 10% over the past year.
View GrowthManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet, market reaction to earnings.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationRelatively steady — typically moves about 1% a day.
View RiskAbbVie’s growth depends on its strong pipeline and recent regulatory approvals. The company recently announced the approval of Tepkinly for lymphoma treatment. Revenue growth is supported by the $10.9 billion Apogee deal, enhancing its immunology leadership. AbbVie trades at 25× P/E, above the peer median of 21×. This suggests the price reflects less growth than expected. If AbbVie cuts guidance on the next call, it could negatively impact the stock. Peer multiples imply a price about 9% below where it trades.
Trailing returns as of 2026-07-07. ABBV is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 31 analysts currently covering ABBV (as of Jul 2026).
Based on 8 Wall Street analysts offering 12-month price targets for ABBV in the last 4 months.
A consensus fair price across 11 valuation methods, at three horizons. Current price $254.64. As of 2026-07-08. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Advances: Advance pipeline and regulatory approvals
Approval supports pipeline advancement and regulatory objectives.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-07-07. EPS is implied from price ÷ P/E. Not investment advice.
Current $254.64
The last 12 months of price, then the range of analyst 12-month targets from today’s $254.64.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Congressional probe may hinder regulatory approvals.
Advances: Advance pipeline and regulatory approvals
New milestone supports pipeline advancement and regulatory approvals.
Investigation could impact reputation and regulatory standing.
Investigation may affect future business operations.
Ongoing investigation could lead to regulatory scrutiny.
Potential legal issues may hinder business growth.
The acquisition could enhance growth and pipeline advancement.